- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.01. | What Sanofi's multiple sclerosis troubles could mean for the space | ||
| 13.01. | AbbVie pledges $100B to US production in drug pricing deal with Trump | ||
| 12.01. | JPM26: US biotech's 'Sputnik moment,' Pfizer's obesity ambitions and Bristol Myers' big year | ||
| 12.01. | AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations | ||
| 12.01. | Best practices for COA selection: Building a stronger foundation for clinical trials | ||
| 12.01. | Building more sustainable cold chain packaging through innovation | ||
| 12.01. | 5 questions facing biopharma in 2026 | ||
| 09.01. | Insmed's 'ginormous' lung drug sales; J&J's US pricing deal | ||
| 09.01. | Aurora sets out to capitalize on FDA's new framework for bespoke drug therapies | ||
| 08.01. | Alveus launches with $160M to advance MariTide-like obesity drug | ||
| 08.01. | Parabilis, chasing 'undruggable' targets, nabs $305M amid VC funding blitz | ||
| 08.01. | Diagonal banks another $125M for 'clustering' antibody drugs | ||
| 08.01. | EpiBiologics raises $107M for its protein-degrading cancer drug | ||
| 07.01. | Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs | ||
| 07.01. | GSK, Ionis claim study success for RNA-based hepatitis B drug | ||
| 07.01. | Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug | ||
| 07.01. | 5 FDA decisions to watch in the first quarter of 2026 | ||
| 06.01. | Alumis soars as TYK2 drug hits mark in psoriasis trials | ||
| 06.01. | Amgen buys protein-degrading startup Dark Blue for up to $840M | ||
| 06.01. | CDC, following Trump's orders, weakens US stance on childhood vaccinations | ||
| 05.01. | Surfing the AI wave: How pharma can harness agents in ERP | ||
| 05.01. | Moderna, searching for a rebound, to seek approval of mRNA flu shot | ||
| 05.01. | Zenas shares crash after top drug misses expectations in immune disease study | ||
| 05.01. | Novo launches Wegovy pill; Argenx to swap CEOs | ||
| 05.01. | Strategic diagnostic testing partnerships are accelerating clinical research |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.